Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Get Free Report) rose 4.3% during trading on Wednesday . The company traded as high as $3.90 and last traded at $3.89. Approximately 889 shares were traded during trading, a decline of 94% from the average daily volume of 14,306 shares. The stock had previously closed at $3.73.
Molecular Partners Price Performance
The stock has a market capitalization of $161.86 million, a PE ratio of -2.09 and a beta of 1.10. The firm's 50 day simple moving average is $3.77 and its 200 day simple moving average is $4.24.
Molecular Partners (NASDAQ:MOLN - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.11). Analysts expect that Molecular Partners AG Sponsored ADR will post -1.93 earnings per share for the current fiscal year.
Institutional Trading of Molecular Partners
A hedge fund recently raised its stake in Molecular Partners stock. BVF Inc. IL lifted its stake in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Free Report) by 205.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,353,968 shares of the company's stock after purchasing an additional 910,747 shares during the period. BVF Inc. IL owned about 3.35% of Molecular Partners worth $6,458,000 at the end of the most recent quarter. Institutional investors own 26.55% of the company's stock.
Molecular Partners Company Profile
(
Get Free Report)
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
Recommended Stories
Before you consider Molecular Partners, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Molecular Partners wasn't on the list.
While Molecular Partners currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access